Status:
RECRUITING
ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
Patients with tandem lesions (TL) are defined as patients with an acute ischemic stroke (AIS) with occlusion of an intracranial vessel of the anterior circulation and an occlusion or severe stenosis (...
Eligibility Criteria
Inclusion
- Patients with acute ischemic stroke of the anterior territory secondary to a tandem lesion, with an indication for thrombectomy treatment according to the current recommendations of the Clinical Practice Guidelines, and the need for cervical stent placement.
- The intracranial occlusion locations that may be included are: carotid "T", M1 and M2 segments of the middle cerebral artery, segment A1 of the anterior cerebral artery; and in the case that the posterior cerebral artery has fetal origin and is the site of intracranial occlusion.
- ASPECTS (Alberta Stroke Program Early computerized Tomography Score) ≥6.
- Greater than or equal to 18 years of age.
- Signed informed consent.
Exclusion
- Patients under 18 years of age.
- Patients with ASPECTS \<6.
- Bilateral strokes or those produced by simultaneous occlusion of an artery in the anterior and posterior territory.
- Patients whose carotid stenosis is due to a re-stenosis or reocclusion of a pre-existing cervical stent.
- Candidate patients for carotid puncture.
- Previous treatment with double antiplatelet therapy for another cause prior to inclusion.
- Severe comorbidity and / or reduced life expectancy.
- Modified Rankin scale (mRS)\> 2.
- Severe allergy to contrast medium.
- Pregnant.
- Patients with intracranial occlusive arteriosclerotic disease or extra or intracranial dissection.
- Documented allergy to acetylsalicylic acid or Tirofiban.
- Personal history of platelet penia (Platelets \<100,000)
- Concomitant anticoagulant treatment with presence of International Normalized Ratio (INR) \> 1.7 in case of anti-vitamin K treatment or taking direct oral anticoagulant \<48 hours ago)
- Medical history of the patient that carries a high risk of bleeding according to the investigator's criteria.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT05225961
Start Date
May 1 2022
End Date
December 1 2025
Last Update
March 7 2024
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Germans Trias i Pujol Hospital
Badalona, Barcelona, Spain
2
Complexo Hospitalario Universitario A Coruña
A Coruña, Spain
3
General Hospital Dr. Balmis (Alicante)
Alicante, Spain
4
Complejo Hospitalario Torrecárdenas
Almería, Spain